Li Wenhui, Li Xingxing, Li Yannan, Chen Yi, Zhu Lingqun, Guo Rongjuan
Department of Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China.
Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing Key Laboratory of Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China.
J Psychiatr Res. 2023 Jan;157:132-140. doi: 10.1016/j.jpsychires.2022.11.028. Epub 2022 Nov 27.
Currently, depression is diagnosed on the basis of neuropsychological examinations and clinical symptoms, and there is no objective diagnostic method. Several studies have explored the application of microRNAs as potential biomarkers diagnostic for depression. This study aims to determine the diagnostic value of microRNAs for depression.
PubMed, Embase, the Cochrane Library, the Web of Science, Wanfang Database, SINOMED, China Science and Technology Journal Databaseand China National Knowledge Infrastructure were searched up to 11 January 2022. Stata (version 16.0) and RevMan (version 5.3) software were used for meta-analysis. The pooled sensitivity, pooled specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio (DOR) were calculated; the summary receiver operating characteristic (SROC) curve was plotted, and the area under the curve (AUC) was calculated. Moreover, meta-regression analyses were performed to determine the source of heterogeneity. Deeks' funnel plot test was used to assess publication bias.
In total, 677 patients were enrolled, including 364 patients with depression and 313 healthy controls. Meta-analysis results showed that the pooled sensitivity, specificity, and DOR of microRNAs for the diagnosis of depression were 0.82 [95% confidence intervals(CI): 0.76, 0.87], 0.70 (95% CI: 0.62, 0.77), and 11 (95% CI: 6, 20), respectively, and the AUC of the SROC was 0.84 (95% CI: 0.80, 0.87).
MicroRNAs have high sensitivity and specificity in diagnosing depression and are potential diagnostic biomarkers for depression.
PROSPERO CRD42022303616.
目前,抑郁症是根据神经心理学检查和临床症状进行诊断的,尚无客观的诊断方法。多项研究探讨了微小RNA作为抑郁症潜在生物标志物诊断的应用。本研究旨在确定微小RNA对抑郁症的诊断价值。
检索截至2022年1月11日的PubMed、Embase、Cochrane图书馆、Web of Science、万方数据库、中国生物医学文献数据库、中国科技期刊数据库和中国知网。使用Stata(版本16.0)和RevMan(版本5.3)软件进行荟萃分析。计算合并敏感性、合并特异性、阳性似然比、阴性似然比和诊断比值比(DOR);绘制汇总受试者工作特征(SROC)曲线,并计算曲线下面积(AUC)。此外,进行荟萃回归分析以确定异质性来源。使用Deeks漏斗图检验评估发表偏倚。
共纳入677例患者,其中抑郁症患者364例,健康对照313例。荟萃分析结果显示,微小RNA诊断抑郁症的合并敏感性、特异性和DOR分别为0.82 [95%置信区间(CI):0.76,0.87]、0.70(95% CI:0.62,0.77)和11(95% CI:6,20),SROC的AUC为0.84(95% CI:0.80,0.87)。
微小RNA在抑郁症诊断中具有较高的敏感性和特异性,是抑郁症潜在的诊断生物标志物。
PROSPERO CRD42022303616。